This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 35Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2095 | IRF1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Cancer v/s Normal | FDR <0.01 | Cells | 26811688 |
2096 | GBP1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2097 | ICAM1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2098 | Foxa1 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2099 | DHCR7 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2100 | HMGCS2 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2101 | MSMO1 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2132 | CYP3A4 | Protein | Human | Upregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, | Prognostic | HCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage | p < 0.05 | Tissue and Cells | 23891548 |
2167 | CORO1C | Protein | Human | Upregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients | Prognostic | Agressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage | p < 0.05 | Tissue and Cells | 20181269 |
2168 | CYP1A1 | RNAs | Human cell lines | Upregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2169 | CYP1B1 | RNAs | Human cell lines | Upregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2170 | GDF15 | RNAs | Human cell lines | Upregulated in hepatoma cell | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2171 | SERPINE1 | RNAs | Human cell lines | Upregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2172 | SOS1 | RNAs | Human cell lines | Upregulated in hepatoma cell | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2173 | RASD1 | RNAs | Human cell lines | Upregulated in hepatoma cell | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2174 | MRAS | RNAs | Human cell lines | Upregulated in hepatoma cell | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2175 | NR1H4 | RNAs | Human cell lines | Downregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2176 | PALMD | RNAs | Human cell lines | Downregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2177 | TXNIP | RNAs | Human cell lines | Downregulated in hepatoma cells | Potential Predictive * | Normal vs hepatoma cells treated with emodin | p < 0.0001 | Cells | 19895793 |
2178 | miR-122 | miRNA | Human | variable expression between different hepatoma cell lines: PLC/PRF/5, Huh-1, and Hep40 exhibited very high levels of miR-122, whereas others, such as Hep3B and HepG2, expressed little or did not express miR-122 at all (e.g. SNU387, and SNU398) ; in HCC patients miR-122 was specifically repressed in | Diagnostic and Prognostic | Normal vs HCC; associated with survival, tumor size and differentiation status | p < 0.001 | Tissue and Cells | 19617899 |
2198 | miR-26a | miRNA | Human cell line | Downregulated in HepG2 cells | Potential Diagnostic * | Normal cell line vs Liver cancer cell line | p < 0.05 | Cells | 29430178 |
2266 | AURKB-Sv2 variant | RNAs | Human | Upregulated in metastatic HCC than primary HCC and Absent in normal | Prognostic | Metastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period | p < 0.01 | Cell line and Tissue | 19134008 |
2361 | UBA2 | RNAs | Human cell line | Upregulated in IFN-alpha drug-tolerant cells | Potential Predictive * | IFN-α treatment tolerant v/s non tolerant cells | FDR <0.5%. | Cell line | 15709204 |
2362 | ZNF185 | RNAs | Human cell line | Upregulated in IFN-alpha drug-tolerant cells | Potential Predictive * | IFN-α treatment tolerant v/s non tolerant cells | FDR <0.5%. | Cell line | 15709204 |
2363 | FOXF1 | RNAs | Human cell line | Upregulated in IFN-alpha drug-tolerant cells | Potential Predictive * | IFN-α treatment tolerant v/s non tolerant cells | FDR <0.5%. | Cell line | 15709204 |
2364 | UBE4B | RNAs | Human cell line | Downregulated in IFN-alpha drug-tolerant cells | Potential Predictive * | IFN-α treatment tolerant v/s non tolerant cells | FDR <0.5%. | Cell line | 15709204 |
2428 | IGFBP7 | Protein and RNAs | Human | Downregulated in IFN-resistant cells (with fold change 2.963) | Predictive | IGFBP7-positive HCC patients v/s IGFBP7-negative HCC patients | p < 0.05 | Cell line and Tissue | 20407444 |
2463 | CLU | RNAs | Human | Upregulated in metastatic HCC than primary HCC | Diagnostic and Prognostic | Primary and metastatic HCC | p < 0.001 | Cell line and Tissue | 16247463 |
2498 | TGM2 | Protein | Human | Upregulated in HCC than non tumor | Diagnostic | HCC v/s normal | p < 0.05 | Cell line, Tissue, Serum | 18646787 |
2507 | SGCE | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
2508 | PEG10 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
2509 | CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
2517 | FGG | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
2518 | FGL1 | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |
2519 | Alpha-2-plasmin inhibitor, SERPINF2 | Protein | Human | Downregulated in HCC than non-tumor (with 100 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 16980951 |